Drug intelligence / Profile preview

VS101

Development stage: Phase 2
Lead developer: BioLight Life Sciences
Modality: Small Molecules
Administration: Subconjunctival

Overview

VS101 is a sustained-release subconjunctival insert developed by ViSci Ltd. It is designed to deliver latanoprost for the treatment of open-angle glaucoma and ocular hypertension. The insert aims to reduce intraocular pressure by increasing uveoscleral outflow, similar to topical latanoprost, but offers the benefit of eliminating the need for daily eye drops, thereby improving patient compliance.

Other names: Eye-D VS-101

Targets

PTGFR (Prostaglandin F2 alpha receptor)

Beyond the preview

Go deeper on VS101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VS101.

Explore the full profile